Little Dermira’s shares zoom up on promising PhIIb atopic dermatitis data — but the road ahead is ultra risky and flanked by heavily armed giants
Just over 18 months since Dermira agreed to pay Roche some $135 million in near-term cash for its disappointing IL-13 anti-inflammatory drug lebrikizumab, hustling it straight into a $200 million mid-stage study for atopic dermatitis, the biotech claims to have the efficacy data to back up its claims that they have a blockbuster on their hands.
Now they’re running it into a pivotal program, long after the drug floundered in asthma under the pharma giant.
Little Dermira is taking on the 600-pound gorilla in atopic dermatitis: the IL-13/IL-4 drug Dupixent, from Regeneron and Sanofi. And it won’t be easy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.